Revenue: As of FY2025 Q3, the actual value is USD 212 K, beating the estimate of USD 66.67 K.EPS: As of FY2025 Q3, the actual value is USD 0.36, beating the estimate of USD -0.2133.EBIT: As of FY2025 Q3, the actual value is USD -7.387 M.<h3>Segment Revenue</h3><ul><li>Collaboration and License Revenue: $212,000 for the three months ended September 30, 2025, compared to $299,000 for the same period in 2024. For the nine months ended September 30, 2025, revenue was $636,000 compared to $598,000 in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income (Loss): Net income of $16,016,000 for the three months ended September 30, 2025, compared to a net loss of $11,466,000 for the same period in 2024. For the nine months ended September 30, 2025, a net loss of $3,126,000 was reported, compared to a net loss of $46,731,000 in 2024.</li><li>Research and Development Expenses: $4,143,000 for the three months ended September 30, 2025, compared to $8,240,000 for the same period in 2024. For the nine months ended September 30, 2025, expenses were $15,942,000 compared to $34,122,000 in 2024.</li><li>General and Administrative Expenses: $2,994,000 for the three months ended September 30, 2025, compared to $4,125,000 for the same period in 2024. For the nine months ended September 30, 2025, expenses were $11,346,000 compared to $15,364,000 in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $25,134,000 for the nine months ended September 30, 2025, compared to - $39,420,000 for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $43,343,000 for the nine months ended September 30, 2025, compared to $35,065,000 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $10,000 for the nine months ended September 30, 2025, compared to $5,181,000 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Gain on Sale of Joint Venture: $22,479,000 for the three months ended September 30, 2025, compared to $251,000 for the same period in 2024. For the nine months ended September 30, 2025, the gain was $22,771,000 compared to $561,000 in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to focus on the development of RLYB116, a C5 inhibitor, with ongoing clinical trials and expects to report data in the fourth quarter of 2025. The company also plans to advance RLYB332, a long-acting MTP-2 antibody, currently in preclinical development.</li><li>Non-Core Business: The company has discontinued the RLYB212 program for FNAIT due to insufficient PK data and has sold its interest in REV102 to Recursion Pharmaceuticals, receiving $20 million in the third quarter of 2025.</li></ul>

Rallybio | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 212 K